1,4-dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (Part 1): Action in ion channels and GPCRs

Current Medicinal Chemistry

Volumn 18, Issue 32, 2011, Pages 4901-4922

  Ioan, P ^a   Carosati, E ^b   Micucci, M ^a   Cruciani, G ^b   Broccatelli, F ^b   Zhorov, B S ^c,d   Chiarini, A ^a   Budriesi, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

^d SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

1,4 DHPs; 1,4 Dihydropyridine scaffold; 1,4 Dihydropyridines; Calcium antagonists; G protein coupled receptors; Ion Channels; L Type Calcium Channel blockers; Ligand Gated Ion Channels; Modulators; Multi target ligand; Therapeutic applications; Voltage Gated Calcium Channels

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; 4 (2,1,3 BENZOOXADIAZOL 4 YL) 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 3 PYRIDINECARBOXYLIC ACID ISOPROPYL ESTER; AMLODIPINE; AMLODIPINE BESYLATE; APJ 2708; ARANIDIPINE; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL L TYPE; CARDEN; CARDIF; CEREBROCRAST; CILNIDIPINE; CLEVIDIPINE; DILTIAZEM; EFONIDIPINE; FELODIPINE; G PROTEIN COUPLED RECEPTOR; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; MADIPINE; MANIDIPINE; MEPIRODIPINE; NICARDIPINE; NIFEDIPINE; NIGULDIPINE; NILVADIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; NITREPIN; PPK 5; PRANIDIPINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENANTIOMER; GENE MUTATION; HEART MUSCLE; HUMAN; MUSCLE RELAXATION; NONHUMAN; PHYTOCHEMISTRY; SEQUENCE HOMOLOGY; SKELETAL MUSCLE; STRUCTURE ACTIVITY RELATION; UTERUS RELAXATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CHEMISTRY, PHARMACEUTICAL; DIHYDROPYRIDINES; HUMANS; ION CHANNELS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80054860325     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797535173     Document Type: Article

References (206)

1. Hantzsch, A. Condensationprodukte aus Aldehydammoniak und Ketoniartigen Verbindungen. Chemische Berichte 1881, 14, 1637-1638.
2. Philipps, A.P.; Randall, L.D. Quinoline substituted dihydropyridines. U.S. Patent 2,359,329 October 3, 1944.
3. Bossert, F.; Vater, W. 1,4-Dihydropyridines-a Basis for Developing New Drugs. Med. Res. Rev., 1989, 9, 291-324. (Pubitemid 19189686)
4. Bossert, F.; Vater, W. Dihydropyridines, a new group of strongly effective coronary therapeutic agents. Naturwissenschaften, 1971, 58, 578.
5. Horton, D.A.; Bourne, G.T.; Smythe, M.L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev., 2003, 103, 893-930.
6. 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (Part 2): Action in other targets and antitargets, Carosati, E.; Ioan, P.; Micucci, M.; Broccatelli, F.; Cruciani, G.; Zhorov, B.S.; Chiarini, A.; Budriesi, R. In preparation.
7. Camerino, D.C.; Desaphy, J.F.; Tricarico, D.; Pierno, S.; Liantonio, A. Therapeutic approaches to ion channel diseases. Adv. Genet., 2008, 64, 81-145.
8. Hering, S.; Hughes, A.D.; Timin, E.N.; Bolton, T.B. Modulation of calcium channels in arterial smooth muscle cells by dihydropyridine enantiomers. J. Gen. Physiol., 1993, 101, 393-410. (Pubitemid 23106913)
9. Ertel, E.A.; Campbell, K.P.; Harpold, M.M.; Hofmann, F.; Mori, Y.; Perez-Reyes, E.; Schwartz, A.; Snutch, T.P.; Tanabe, T.; Birnbaumer, L.; Tsien, R.W.; Catterall, W.A. Nomenclature of voltage-gated calcium channels. Neuron, 2000, 25, 533-535.
10. Welling, A.; Ludwig, A.; Zimmer, S.; Klugbauer, N.; Flockerzi, V.; Hofmann, F. Alternatively spliced IS6 segments of the alpha(1C) gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2+ channels. Circ. Res., 1997, 81, 526-532. (Pubitemid 27432739)
11. Bean, B.P. Nitrendipine block of cardiac calcium channels: High-affinity binding to the inactivated state. P. Natl. Acad. Sci. USA, 1984, 81, 6388-6392. (Pubitemid 15220843)
12. Sanguinetti, M.C.; Kass, R.S. Voltage-dependent block of calcium channel current in the calf cardiac Purkinje fiber by dihydropyridine calcium channel antagonists. Circ. Res., 1984, 55, 336-348. (Pubitemid 14047495)
13. Hernandez-Hernandez, R.; Velasco, M.; Armas-Hernandez, M.J.; Armas-Padilla, M.C. Update on the use of calcium antagonists on hypertension. J. Hum. Hypertens., 2002, 16 Suppl 1, S114-117. (Pubitemid 34441146)
14. Striessnig, J. Pharmacology, structure and function of cardiac L-type Ca2+ channels. Cell. Physiol. Biochem., 1999, 9, 242-269.
15. Catterall, W.A. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron., 2000, 26, 13-25.
16. Hockerman, G.H.; Peterson, B.Z.; Johnson, B.D.; Catterall, W.A. Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 361-396. (Pubitemid 27238881)
17. Ito, H.; Klugbauer, N.; Hofmann, F. Transfer of the high affinity dihydropyridine sensitivity from L-type To non-L-type calcium channel. Mol. Pharmacol., 1997, 52, 735-740. (Pubitemid 27443996)
18. Sinnegger, M.J.; Wang, Z.; Grabner, M.; Hering, S.; Striessnig, J.; Glossmann, H.; Mitterdorfer, J. Nine L-type amino acid residues confer full 1,4-dihydropyridine sensitivity to the neuronal calcium channel alpha1A subunit. Role of L-type Met1188. J. Biol. Chem., 1997, 272, 27686-27693. (Pubitemid 27473564)
19. Striessnig, J.; Grabner, M.; Mitterdorfer, J.; Hering, S.; Sinnegger, M.J.; Glossmann, H. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol. Sci., 1998, 19, 108-115. (Pubitemid 28197812)
20. Fossheim, R.; Svarteng, K.; Mostad, A.; Romming, C.; Shefter, E.; Triggle, D.J. Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine. J. Med. Chem., 1982, 25, 126-131. (Pubitemid 12106630)
21. Rovnyak, G.C.; Kimball, S.D.; Beyer, B.; Cucinotta, G.; Dimarco, J.D.; Gougoutas, J.; Hedberg, A.; Malley, M.; Mccarthy, J.P.; Zhang, R.A.; Moreland, S. Calcium-Entry Blockers and Activators-Conformational and Structural Determinants of Dihydropyrimidine Calcium-Channel Modulators. J. Med. Chem., 1995, 38, 119-129.
22. Jauk, B.; Pernat, T.; Kappe, C.O. Design and synthesis of a conformationally rigid mimic of the dihydropyrimidine calcium channel modulator SQ 32,926. Molecules, 2000, 5, 227-239. (Pubitemid 39016385)
23. Mahmoudian, M.; Richards, W.G. A Conformational Distinction between Dihydropyridine Calcium Agonists and Antagonists. J. Chem. Soc. Chem. Comm., 1986, 739-741. (Pubitemid 17011726)
24. Mahmoudian, M.; Richards, W.G. Qsar of Binding of Dihydropyridine-Type Calcium-Antagonists to Their Receptor on Ileal Smooth-Muscle Preparations. J. Pharm. Pharmacol., 1986, 38, 272-276. (Pubitemid 16104213)
25. Langs, D.A.; Triggle, D.J. Conformational Features of Calcium-Channel Agonist and Antagonist Analogs of Nifedipine. Mol. Pharmacol., 1985, 27, 544-548. (Pubitemid 15098311)
26. Goldmann, S.; Stoltefuss, J. 1,4-Dihydropyridines: Effects of Chirality and Conformation on the Calcium Antagonist and Calcium Agonist Activities-Goldmann-2003-Angewandte Chemie International Edition in English-Wiley Online Library. 1991, 30, 1559-1578.
27. Miri, R.; Javidnia, K.; Sarkarzadeh, H.; Hemmateenejad, B. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist. Bioorg. Med. Chem., 2006, 14, 4842-4849.
28. Handrock, R.; Herzig, S. Stereoselectivity of Ca2+ channel block by dihydropyridines: No modulation by the voltage protocol. Eur. J. Pharmacol., 1996, 309, 317-321. (Pubitemid 26273751)
29. O'Neill, S.K.; McKay, D.W.; Campbell, N.; Triggle, C.R.; Crowley, M.; Bolger, G.T. Comparative behavioral, neurochemical and pharmacological activities of dihydropyridine calcium channel activating drugs. J. Pharmacol. Exp. Ther., 1990, 253, 905-912. (Pubitemid 20209343)
30. Triggle, D.J. 1,4-dihydropyridines as calcium channel ligands and privileged structures. Cell. Mol. Neurobiol., 2003, 23, 293-303. (Pubitemid 36676276)
31. Zamponi, G.W.; Stotz, S.C.; Staples, R.J.; Andro, T.M.; Nelson, J.K.; Hulubei, V.; Blumenfeld, A.; Natale, N.R. Unique structure-activity relationship for 4-isoxazolyl-1,4-dihydropyridines. J. Med. Chem., 2003, 46, 87-96. (Pubitemid 36043788)
32. Budriesi, R.; Aicardi, G.; Campana, G.; Spampinato, S.; Zaza, A.; Bisi, A.; Rampa, A.; Valenti, P.; Chiarini, A. Selective cardiodepressant activity of fluodipine, a fluorenone-1,4-dihydropyridine derivative. Eur. J. pharmacol., 1998, 359, 161-170. (Pubitemid 28513012)
33. Budriesi, R.; Bisi, A.; Ioan, P.; Rampa, A.; Gobbi, S.; Belluti, F.; Piazzi, L.; Valenti, P.; Chiarini, A. 1,4-Dihydropyridine derivatives as calcium channel modulators: The role of 3-methoxy-flavone moiety. Bioorg. Med. Chem., 2005, 13, 3423-3430. (Pubitemid 40552862)
34. Budriesi, R.; Ioan, P.; Locatelli, A.; Cosconati, S.; Leoni, A.; Ugenti, M.P.; Andreani, A.; Di Toro, R.; Bedini, A.; Spampinato, S.; Marinelli, L.; Novellino, E.; Chiarini, A. Imidazo[2,1-b]thiazole system: A scaffold endowing dihydropyridines with selective cardiodepressant activity. J. Med. Chem., 2008, 51, 1592-1600. (Pubitemid 351438843)
35. Takahashi, D.; Oyunzul, L.; Onoue, S.; Ito, Y.; Uchida, S.; Simsek, R.; Gunduz, M.G.; Safak, C.; Yamada, S. Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Biol. Pharm. Bull., 2008, 31, 473-479. (Pubitemid 351442149)
36. Gordeev, M.F.; Patel, D.V.; England, B.P.; Jonnalagadda, S.; Combs, J.D.; Gordon, E.M. Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers. Bioorg. Med. Chem., 1998, 6, 883-889. (Pubitemid 28464518)
37. Coburn, R.A.; Wierzba, M.; Suto, M.J.; Solo, A.J.; Triggle, A.M.; Triggle, D.J. 1,4-Dihydropyridine antagonist activities at the calcium channel: A quantitative structure-activity relationship approach. J. Med. Chem., 1988, 31, 2103-2107.
38. Mahmoudian, M.; Richards, W.G. A Quantum chemical study of structureactivity relationships of dihydropyridine calcium antagonists. J. Sci. IR. Iran 1990, 1, 261-265.
39. Hemmateenejad, B.; Miri, R.; Akhond, M.; Shamsipur, M. Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method. Arch. Pharm. (Weinheim), 2002, 335, 472-480. (Pubitemid 36125515)
40. Hemmateenejad, B.; Miri, R.; Akhond, M.; Shamsipur, M. QSAR study of the calcium channel antagonist activity of some recently synthesized dihydropyridine derivatives. An application of genetic algorithm for variable selection in MLR and PLS methods. Chemometr. Intell. Lab., 2002, 64, 91-99. (Pubitemid 35304562)
41. Hemmateenejad, B.; Akhond, M.; Miri, R.; Shamsipur, M. Genetic algorithm applied to the selection of factors in principal component-artificial neural networks: Application to QSAR study of calcium channel antagonist activity of 1,4-dihydropyridines (nifedipine analogous). J. Chem. Inf. Comput. Sci., 2003, 43, 1328-1334.
42. Schleifer, K.J.; Tot, E. CoMFA, CoMSIA and GRID/GOLPE studies on calcium entry blocking 1,4-dihydropyridines. Quant. Struct-Act. Rel., 2002, 21, 239-248. (Pubitemid 34951594)
43. Yamaguchi, S.; Okamura, Y.; Nagao, T.; Adachi-Akahane, S. Serine residue in the IIIS5-S6 linker of the L-type Ca2+ channel alpha 1C subunit is the critical determinant of the action of dihydropyridine Ca2+ channel agonists. J. Biol. Chem., 2000, 275, 41504-41511. (Pubitemid 32054987)
44. Zhorov, B.S.; Folkman, E.V.; Ananthanarayanan, V.S. Homology model of dihydropyridine receptor: Implications for L-type Ca2+ channel modulation by agonists and antagonists. Arch. Biochem. Biophys., 2001, 393, 22-41. (Pubitemid 32808356)
45. Doyle, D.A.; Morais Cabral, J.; Pfuetzner, R.A.; Kuo, A.; Gulbis, J.M.; Cohen, S.L.; Chait, B.T.; MacKinnon, R. The structure of the potassium channel: Molecular basis of K+ conduction and selectivity. Science, 1998, 280, 69-77. (Pubitemid 28169082)
46. Zhorov, B.S.; Ananthanarayanan, V.S. Structural model of a synthetic Ca2+ channel with bound Ca2+ ions and dihydropyridine ligand. Biophys. J., 1996, 70, 22-37.
47. Lipkind, G.M.; Fozzard, H.A. Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the L-type Ca2+ channel. Mol. Pharmacol., 2003, 63, 499-511. (Pubitemid 36297319)
48. Cosconati, S.; Marinelli, L.; Lavecchia, A.; Novellino, E. Characterizing the 1,4-dihydropyridines binding interactions in the L-type Ca2+ channel: Model construction and docking calculations. J. Med. Chem., 2007, 50, 1504-1513. (Pubitemid 46564372)
49. Cordero-Morales, J.F.; Cuello, L.G.; Zhao, Y.; Jogini, V.; Cortes, D.M.; Roux, B.; Perozo, E. Molecular determinants of gating at the potassiumchannel selectivity filter. Nat. Struct. Mol. Biol., 2006, 13, 311-318. (Pubitemid 43873501)
50. Tikhonov, D.B.; Zhorov, B.S. Structural model for dihydropyridine binding to L-type calcium channels. J. Biol. Chem., 2009, 284, 19006-19017.
51. Akaike, N.; Kanaide, H.; Kuga, T.; Nakamura, M.; Sadoshima, J.; Tomoike, H. Low-Voltage-Activated Calcium Current in Rat Aorta Smooth-Muscle Cells in Primary Culture. J. Physiol-London, 1989, 416, 141-160. (Pubitemid 19223208)
52. Takahashi, K.; Akaike, N. Nicergoline Inhibits T-Type Ca2+ Channels in Rat Isolated Hippocampal Ca1 Pyramidal Neurons. Brit. J. Pharmacol., 1990, 100, 705-710. (Pubitemid 20233306)
53. Leenen, F.H. Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines. Am. J. Hypertens., 1996, 9, 97S-104S.
54. Freedman, D.D.; Waters, D.D. 'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications. Drugs, 1987, 34, 578-598. (Pubitemid 17147674)
55. Lüscher, T.F.; Cosentino, F. The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal. Drugs, 1998, 55, 509-517. (Pubitemid 28162070)
56. Tokushima, T.; Utsunomiya, T.; Ogawa, T.; Kidoh, K.; Ohtsubo, Y.; Ryu, T.; Yoshida, K.; Ogata, T.; Tsuji, S.; Matsuo, S. Short-and long-term effects of nisoldipine on cardiac function and exercise tolerance in patients with hypertrophic cardiomyopathy. Basic. Res. Cardiol., 1996, 91, 329-336. (Pubitemid 26280529)
57. Herrick, A. Raynaud's phenomenon. Curr. Treat Options Cardiovasc. Med., 2008, 10, 146-155. (Pubitemid 351485949)
58. Tomassoni, D.; Lanari, A.; Silvestrelli, G.; Traini, E.; Amenta, F. Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies. Clin. Exp. Hypertens., 2008, 30, 744-766.
59. Romero, M.; Sanchez, I.; Pujol, M.D. New advances in the field of calcium channel antagonists: Cardiovascular effects and structure-activity relationships. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2003, 1, 113-141.
60. Joslyn, A.F.; Luchowski, E.; Triggle, D.J. Dimeric 1,4-Dihydropyridines as Calcium-Channel Antagonists. J. Med. Chem., 1988, 31, 1489-1492.
61. Striessnig, J.; Bolz, H.J.; Koschak, A. Channelopathies in Cav1.1, Cav1.3, and Cav1.4 voltage-gated L-type Ca2+ channels. Pflugers Arch. 2010, 460, 361-74.
62. Hell, J.W.; Westenbroek, R.E.; Warner, C.; Ahlijanian, M.K.; Prystay, W.; Gilbert, M.M.; Snutch, T.P.; Catterall, W.A. Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. J. Cell. Biol., 1993, 123, 949-962. (Pubitemid 23333582)
63. Sinnegger-Brauns, M.J.; Huber, I.G.; Koschak, A.; Wild, C.; Obermair, G.J.; Einzinger, U.; Hoda, J.C.; Sartori, S.B.; Striessnig, J. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol. Pharmacol., 2009, 75, 407-414.
64. Platzer, J.; Engel, J.; Schrott-Fischer, A.; Stephan, K.; Bova, S.; Chen, H.; Zheng, H.; Striessnig, J. Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. Cell, 2000, 102, 89-97.
65. Baig, S.M.; Koschak, A.; Lieb, A.; Gebhart, M.; Dafinger, C.; Nürnberg, G.; Ali, A.; Ahmad, I.; Sinnegger-Brauns, M.J.; Brandt, N.; Engel, J.; Mangoni, M.E.; Farooq, M.; Khan, H.U.; Nürnberg, P.; Striessnig, J.; Bolz, H.J. Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Na.t Neurosci. 2011, 14, 77-84.
66. Moosmang, S.; Haider, N.; Klugbauer, N.; Adelsberger, H.; Langwieser, N.; Muller, J.; Stiess, M.; Marais, E.; Schulla, V.; Lacinova, L.; Goebbels, S.; Nave, K.A.; Storm, D.R.; Hofmann, F.; Kleppisch, T. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J. Neurosci., 2005, 25, 9883-9892. (Pubitemid 41528025)
67. Olson, P.A.; Tkatch, T.; Hernandez-Lopez, S.; Ulrich, S.; Ilijic, E.; Mugnaini, E.; Zhang, H.; Bezprozvanny, I.; Surmeier, D.J. G-proteincoupled receptor modulation of striatal CaV1.3 L-type Ca2+ channels is dependent on a Shank-binding domain. J. Neurosci., 2005, 25, 1050-1062. (Pubitemid 40268947)
68. Chan, C.S.; Guzman, J.N.; Ilijic, E.; Mercer, J.N.; Rick, C.; Tkatch, T.; Meredith, G.E.; Surmeier, D.J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature, 2007, 447, 1081-1086. (Pubitemid 47014425)
69. Striessnig, J.; Koschak, A.; Sinnegger-Brauns, M.J.; Hetzenauer, A.; Nguyen, N.K.; Busquet, P.; Pelster, G.; Singewald, N. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem. Soc. Trans., 2006, 34, 903-909. (Pubitemid 44796447)
70. Sinnegger-Brauns, M.J.; Hetzenauer, A.; Huber, I.G.; Renstrom, E.; Wietzorrek, G.; Berjukov, S.; Cavalli, M.; Walter, D.; Koschak, A.; Waldschutz, R.; Hering, S.; Bova, S.; Rorsman, P.; Pongs, O.; Singewald, N.; Striessnig, J.J. Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. J. Clin. Invest., 2004, 113, 1430-1439. (Pubitemid 39071698)
71. Chang, C.C.; Cao, S.; Kang, S.; Kai, L.; Tian, X.; Pandey, P.; Dunne, S.F.; Luan, C.H.; Surmeier, D.J.; Silverman, R.B. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg. Med. Chem., 2010, 18, 3147-3158.
72. Fujii, S.; Kameyama, K.; Hosono, M.; Hayashi, Y.; Kitamura, K. Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther., 1997, 280, 1184-1191. (Pubitemid 27166712)
73. Yamamoto, T.; Niwa, S.; Ohno, S.; Onishi, T.; Matsueda, H.; Koganei, H.; Uneyama, H.; Fujita, S.I.; Takeda, T.; Kito, M.; Ono, Y.; Saitou, Y.; Takahara, A.; Iwata, S.; Shoji, M. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels. Bioorg. Med. Chem. Lett., 2006, 16, 798-802. (Pubitemid 43059825)
74. Yamamoto, T.; Niwa, S.; Ohno, S.; Tokumasu, M.; Masuzawa, Y.; Nakanishi, C.; Nakajo, A.; Onishi, T.; Koganei, H.; Fujita, S.; Takeda, T.; Kito, M.; Ono, Y.; Saitou, Y.; Takahara, A.; Iwata, S.; Shoji, M. The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels. Bioorg. Med. Chem. Letters, 2008, 18, 4813-4816.
75. Masumiya, H.; Shijuku, T.; Tanaka, H.; Shigenobu, K. Inhibition of myocardial L-and T-type Ca2+ currents by efonidipine: Possible mechanism for its chronotropic effect. Eur. JPharmacol., 1998, 349, 351-357. (Pubitemid 28277107)
76. Sugano, N.; Wakino, S.; Kanda, T.; Tatematsu, S.; Homma, K.; Yoshioka, K.; Hasegawa, K.; Hara, Y.; Suetsugu, Y.; Yoshizawa, T.; Hara, Y.; Utsunomiya, Y.; Tokudome, G.; Hosoya, T.; Saruta, T.; Hayashi, K. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int., 2008, 73, 826-834. (Pubitemid 351398286)
77. Horiba, M.; Muto, T.; Ueda, N.; Opthof, T.; Miwa, K.; Hojo, M.; Lee, J.K.; Kamiya, K.; Kodama, I.; Yasui, K. T-type Ca2+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers. Life Sci., 2008, 82, 554-560.
78. Okayama, S.; Imagawa, K.; Naya, N.; Iwama, H.; Somekawa, S.; Kawata, H.; Horii, M.; Nakajima, T.; Uemura, S.; Saito, Y. Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens. Res., 2006, 29, 493-497. (Pubitemid 44363465)
79. Kumar, P.P.; Stotz, S.C.; Paramashivappa, R.; Beedle, A.M.; Zamponi, G.W.; Rao, A.S. Synthesis and evaluation of a new class of nifedipine analogs with T-type calcium channel blocking activity. Mol. Pharmacol., 2002, 61, 649-658. (Pubitemid 34171931)
80. Drígelová, M.; Tarabova, B.; Duburs, G.; Lacinova, L. The dihydropyridine analogue cerebrocrast blocks both T-type and L-type calcium currents. Can. J. Physiol. Pharmacol., 2009, 87, 923-932.
81. Furukawa, T.; Nukada, T.; Namiki, Y.; Miyashita, Y.; Hatsuno, K.; Ueno, Y.; Yamakawa, T.; Isshiki, T. Five different profiles of dihydropyridines in blocking T-type Ca2+ channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes. Eur. J. Pharmacol., 2009, 613, 100-107.
82. Godfraind, T. Is combined L-and T-channel blockade better than L-channel blockade in therapy? Hypertension, 2009, 54, e3; author reply e4.
83. Lai, F.A.; Erickson, H.P.; Rousseau, E.; Liu, Q.Y.; Meissner, G. Purification and Reconstitution of the Calcium Release Channel from Skeletal-Muscle. Nature, 1988, 331, 315-319. (Pubitemid 18042488)
84. Ledbetter, M.W.; Preiner, J.K.; Louis, C.F.; Mickelson, J.R. Tissue distribution of ryanodine receptor isoforms and alleles determined by reverse transcription polymerase chain reaction. J. Biol. Chem., 1994, 269, 31544-31551. (Pubitemid 24379513)
85. Rosenberg, H.; Davis, M.; James, D.; Pollock, N.; Stowell, K. Malignant hyperthermia. Orphanet J. Rare Dis., 2007, 2, 21.
86. Jungbluth, H.; Zhou, H.; Sewry, C.A.; Robb, S.; Treves, S.; Bitoun, M.; Guicheney, P.; Buj-Bello, A.; Bonnemann, C.; Muntoni, F. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromusc. Disord., 2007, 17, 338-345. (Pubitemid 46546523)
87. Zorzato, F.; Jungbluth, H.; Zhou, H.Y.; Muntoni, F.; Treves, S. Functional effects of mutations identified in patients with multiminicore disease. Iubmb Life, 2007, 59, 14-20.
88. Jungbluth, H. Central core disease. Orphanet J. Rare Dis., 2007, 2, 25-33.
89. Marx, S.O.; Reiken, S.; Hisamatsu, Y.; Jayaraman, T.; Burkhoff, D.; Rosemblit, N.; Marks, A.R. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell, 2000, 101, 365-376.
90. Marks, A.R. Ryanodine receptors/calcium release channels in heart failure and sudden cardiac death. J. Mol. Cell. Cardiol., 2001, 33, 615-624. (Pubitemid 32538975)
91. Wehrens, X.H.T.; Lehnart, S.E.; Huang, F.; Vest, J.A.; Reiken, S.R.; Mohler, P.J.; Sun, J.; Guatimosim, S.; Song, L.S.; Rosemblit, N.; D'Armiento, J.M.; Napolitano, C.; Memmi, M.; Priori, S.G.; Lederer, W.J.; Marks, A.R. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell, 2003, 113, 829-840. (Pubitemid 36792028)
92. Lehnart, S.E.; Wehrens, X.H.; Kushnir, A.; Marks, A.R. Cardiac ryanodine receptor function and regulation in heart disease. Ann. N. Y. Acad. Sci., 2004, 1015, 144-159. (Pubitemid 38879486)
93. Galeotti, N.; Quattrone, A.; Vivoli, E.; Norcini, M.; Bartolini, A.; Ghelardini, C. Different involvement of type 1, 2, and 3 ryanodine receptors in memory processes. Learn. Memory, 2008, 15, 315-323. (Pubitemid 351629593)
94. Williams, J.S.; Grupp, I.L.; Grupp, G.; Vaghy, P.L.; Dumont, L.; Schwartz, A.; Yatani, A.; Hamilton, S.; Brown, A.M. Profile of the Oppositely Acting Enantiomers of the Dihydropyridine 202-791 in Cardiac Preparations-Receptor-Binding, Electrophysiological, and Pharmacological Studies. Biochem. Bioph. Res. Co., 1985, 131, 13-21. (Pubitemid 16251112)
95. Sanguinetti, M.C.; Krafte, D.S.; Kass, R.S. Voltage-Dependent Modulation of Ca Channel Current in Heart-Cells by Bay K8644. J. Gen. Physiol., 1986, 88, 369-392. (Pubitemid 16023300)
96. Hof, R.P.; Ruegg, U.T.; Hof, A.; Vogel, A. Stereoselectivity at the calcium channel: Opposite action of the enantiomers of a 1,4-dihydropyridine. J. Cardiovasc. Pharmacol., 1985, 7, 689-693. (Pubitemid 15070341)
97. Kamp, T.J.; Sanguinetti, M.C.; Miller, R.J. Voltage-and use-dependent modulation of cardiac calcium channels by the dihydropyridine (+)-202-791. Circ. Res., 1989, 64, 338-351. (Pubitemid 19054030)
98. Sagawa, T.; Nishio, M.; Sagawa, K.; Kelly, J.E.; Lokuta, A.J.; Tsai, J.; Kan, E.; Wasserstrom, J.A. Activation of purified cardiac ryanodine receptors by dihydropyridine agonists. Am. J. Physiol.-Heart Circul. Physiol., 2001, 280, H1201-H1207.
99. Yatani, A.; Brown, A.M. The Calcium-Channel Blocker Nitrendipine Blocks Sodium-Channels in Neonatal Rat Cardiac Myocytes. Circ. Res., 1985, 56, 868-875. (Pubitemid 15231510)
100. Yatani, A.; Kunze, D.L.; Brown, A.M. Effects of Dihydropyridine Calcium-Channel Modulators on Cardiac Sodium-Channels. Am. J. Physiol., 1988, 254, H140-H147.
101. Bryson, H.M.; Fulton, B.; Benfield, P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs, 1996, 52, 549-563. (Pubitemid 26340539)
102. McGivern, J.G.; Patmore, L.; Sheridan, R.D. Actions of the novel neuroprotective agent, lifarizine (RS-87476), on voltage-dependent sodium currents in the neuroblastoma cell line, N1E-115. Br. J. Pharmacol., 1995, 114, 1738-1744.
103. Miljanich, G.P.; Ramachandran, J. Antagonists of neuronal calcium channels: Structure, function, and therapeutic implications. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 707-734.
104. Cook, N.S. The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol. Sci., 1988, 9, 21-28. (Pubitemid 18030226)
105. Quast, U.; Cook, N.S. Moving together: K+ channel openers and ATPsensitive K+ channels. Trends Pharmacol. Sci., 1989, 10, 431-435. (Pubitemid 19264290)
106. Christie, M.J. Molecular and functional diversity of K+ channels. Clin. Exp. Pharmacol. Physiol., 1995, 22, 944-951.
107. Blatz, A.L.; Magleby, K.L. Calcium-Activated Potassium Channels. Trends Neurosci., 1987, 10, 463-467.
108. Sadoshima, J.; Akaike, N.; Tomoike, H.; Kanaide, H.; Nakamura, M. Ca-Activated K-Channel in Cultured Smooth-Muscle Cells of Rat Aortic Media. Am. J. Physiol., 1988, 255, H410-H418.
109. Williams, D.L.; Katz, G.M.; Roycontancin, L.; Reuben, J.P. Guanosine 5'-Monophosphate Modulates Gating of High-Conductance Ca-2+-Activated K+ Channels in Vascular Smooth-Muscle Cells. P. Natl. Acad. Sci. USA, 1988, 85, 9360-9364. (Pubitemid 19001896)
110. Chandy, K.G.; Grissmer, S.; Gutman, G.A.; Lazdunski, M.; Mckinnon, D.; Pardo, L.A.; Robertson, G.A.; Rudy, B.; Sanguinetti, M.C.; Stühmer, W.; Wang, X. Voltage-Gated Potassium Channels, introductory chapter. Last modified on 2009-10-13. Accessed on 2011-07-28. IUPHAR database, http://www.iuphardb. org/DATABASE/FamilyIntroductionForward?familyId=81.
111. Pongs O. Ins and outs of cardiac voltage-gated potassium channels. Curr. Opin. Pharmacol., 2009, 9, 311-315.
112. Zhang, X.; Anderson, J.W.; Fedida, D. Characterization of nifedipine block of the human heart delayed rectifier, hKV1.5. J. Pharmacol. Exp. Ther., 1997, 281, 1247-1256. (Pubitemid 27258384)
113. Amos, G.J.; Wettwer, E.; Li, Q.; Himmel, H.M.; Ravens, U. Circulation, 1994, 90, I-581a.
114. Vaccaro, W.; Huynh, T.; Lloyd, J.; Atwal, K.; Finlay, H.J.; Levesque, P.; Conder, M.L.; Jenkins-West, T.; Shi, H.; Sun, L. Dihydropyrazolopyrimidine Inhibitors of KV1.5 (IKur). Bioorg. Med. Chem. Lett., 2008, 18, 6381-6385.
115. Lloyd, J.; Finlay, H.J.; Atwal, K.; Kover, A.; Prol, J.; Yan, L.; Bhandaru, R.; Vaccaro, W.; Huynh, T.; Huang, C.S.; Conder, M.; Jenkins-West, T.; Sun, H.; Li, D.; Levesque, P. Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists. Bioorg. Med. Chem. Lett., 2009, 19, 5469-5473.
116. Lloyd, J.; Finlay, H.J.; Vacarro, W.; Hyunh, T.; Kover, A.; Bhandaru, R.; Yan, L.; Atwal, K.; Conder, M.L.; Jenkins-West, T.; Shi, H.; Huang, C.; Li, D.; Sun, H.; Levesque, P. Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers. Bioorg. Med. Chem. Lett., 2010, 20, 1436-1439.
117. Hatano, N.; Ohya, S.; Muraki, K.; Giles, W.; Imaizumi, Y. 3. Dihydropyridine Ca2+ channel antagonists and agonists block KV4.2, KV4.3 and KV1.4 K+ channels expressed in HEK293 cells. Br. J. Pharmacol., 2003, 139, 533-44. (Pubitemid 36819623)
118. Klockner, U.; Isenberg, G. The dihydropyridine niguldipine modulates calcium and potassium currents in vascular smooth muscle cells. Br. J. Pharmacol., 1989, 97, 957-967. (Pubitemid 19168732)
119. Boer, R.; Grassegger, A.; Schudt, C.; Glossmann, H. (+)-Niguldipine Binds with Very High-Affinity to Ca-2+ Channels and to a Subtype of Alpha-1-Adrenoceptors. Eur. J. Pharm.-Molec. Ph., 1989, 172, 131-145. (Pubitemid 19230192)
120. Moynihan, A.T.; Smith, T.J.; Morrison, J.J. The relaxant effect of nifedipine in human uterine smooth muscle and the BK(Ca) channel. Am. J. Obstet. Gynecol., 2008, 198, 237 e231-238.
121. Isomoto, S.; Kondo, C.; Kurachi, Y. Inwardly rectifying potassium channels: Their molecular heterogeneity and function. Jpn. J. Physiol., 1997, 47, 11-39. (Pubitemid 27205023)
122. Aguilar-Bryan, L.; Clement, J.P.t.; Gonzalez, G.; Kunjilwar, K.; Babenko, A.; Bryan, J. Toward understanding the assembly and structure of KATP channels. Physiol. Rev., 1998, 78, 227-245. (Pubitemid 28070980)
123. Faivre, J.F.; Findlay, I. Action-Potential Duration and Activation of Atp-Sensitive Potassium Current in Isolated Guinea-Pig Ventricular Myocytes. Biochimica Et Biophysica Acta, 1990, 1029, 167-172. (Pubitemid 20346436)
124. Dunne, M.J.; Petersen, O.H. Potassium selective ion channels in insulinsecreting cells: Physiology, pharmacology and their role in stimulussecretion coupling. Biochim. Biophys. Acta, 1991, 1071, 67-82. (Pubitemid 121002404)
125. Quayle, J.M.; Standen, N.B. KATP channels in vascular smooth muscle. Cardiovasc. Res., 1994, 28, 797-804.
126. Amoroso, S.; Schmid-Antomarchi, H.; Fosset, M.; Lazdunski, M. Glucose, sulfonylureas, and neurotransmitter release: Role of ATP-sensitive K+ channels. Science, 1990, 247, 852-854.
127. Li, J.H.; Zuzach, J.S.; Kan, S.T., Winter flounder urinary bladder as a model tissue for assessing the potency of thiazide diuretics. In: Diuretics III: Chemistry, Pharmacology and Clinical Applications, Elsevier Science Publishing Co., Inc., New York, 1990.
128. Frank, C.A.; Trainor, D.A.; Forst, J.M.; Grant, T.; Harris, R.J.; Kau, S.T.; Li, J.H.; Ohnmach, C.J.; Smith, R.W.; Trivedi, S. Dihydropyridine KATP potassium channel openers. Bioorg. Med. Chem. Lett., 1993, 3, 2725-2726. (Pubitemid 24041006)
129. Altenbach, R.J.; Brune, M.E.; Buckner, S.A.; Coghlan, M.J.; Daza, A.V.; Fabiyi, A.; Gopalakrishnan, M.; Henry, R.F.; Khilevich, A.; Kort, M.E.; Milicic, I.; Scott, V.E.; Smith, J.C.; Whiteaker, K.L.; Carroll, W.A. Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener. J. Med. Chem., 2006, 49, 6869-6887. (Pubitemid 44754683)
130. Gopalakrishnan, M.; Buckner, S.A.; Whiteaker, K.L.; Shieh, C.C.; Molinari, E.J.; Milicic, I.; Daza, A.V.; Davis-Taber, R.; Scott, V.E.; Sellers, D.; Chess-Williams, R.; Chapple, C.R.; Liu, Y.; Liu, D.; Brioni, J.D.; Sullivan, J.P.; Williams, M.; Carroll, W.A.; Coghlan, M.J. (-)-(9S)-9-(3-Bromo-4- fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quin olin-8(4H)-one 1,1-dioxide (A-278637): A novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization. J. Pharmacol. Exp.Ther., 2002, 303, 379-386.
131. Davis-Taber, R.; Molinari, E.J.; Altenbach, R.J.; Whiteaker, K.L.; Shieh, C.C.; Rotert, G.; Buckner, S.A.; Malysz, J.; Milicic, I.; McDermott, J.S.; Gintant, G.A.; Coghlan, M.J.; Carroll, W.A.; Scott, V.E.; Gopalakrishnan, M [125I]A-312110, a novel high-affinity 1,4-dihydropyridine ATP-sensitive K+ channel opener: Characterization and pharmacology of binding. Mol. Pharmacol., 2003, 64, 143-153. (Pubitemid 36759826)
132. Carroll, W.A.; Altenbach, R.J.; Bai, H.; Brioni, J.D.; Brune, M.E.; Buckner, S.A.; Cassidy, C.; Chen, Y.; Coghlan, M.J.; Daza, A.V.; Drizin, I.; Fey, T.A.; Fitzgerald, M.; Gopalakrishnan, M.; Gregg, R.J.; Henry, R.F.; Holladay, M.W.; King, L.L.; Kort, M.E.; Kym, P.R.; Milicic, I.; Tang, R.; Turner, S.C.; Whiteaker, K.L.; Yi, L.; Zhang, H.; Sullivan, J.P. Synthesis and structureactivity relationships of a novel series of 2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: Discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3, 2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractions. J. Med. Chem., 2004, 47, 3163-3179. (Pubitemid 38713980)
133. Carroll, W.A.; Agrios, K.A.; Altenbach, R.J.; Buckner, S.A.; Chen, Y.; Coghlan, M.J.; Daza, A.V.; Drizin, I.; Gopalakrishnan, M.; Henry, R.F.; Kort, M.E.; Kym, P.R.; Milicic, I.; Smith, J.C.; Tang, R.; Turner, S.C.; Whiteaker, K.L.; Zhang, H.; Sullivan, J.P. Synthesis and structure-activity relationships of a novel series of tricyclic dihydropyridine-based KATP openers that potently inhibit bladder contractions in vitro. J. Med. Chem., 2004, 47, 3180-3192. (Pubitemid 38702710)
134. Liu, H.; Enyeart, J.A.; Enyeart, J.J. Potent inhibition of native TREK-1
135. Lesage, F; Lazdunski, M. Molecular and functional properties of two-poredomain potassium channels. Am. J. Physiol. Renal Physiol., 2000, 279, F793-801.
136. Pilewski, J.M.; Frizzell, R.A. Role of CFTR in airway disease. Physiol. Rev., 1999, 79, S215-255. (Pubitemid 29058916)
137. Sheppard, D.N.; Welsh, M.J. Structure and function of the CFTR chloride channel. Physiol. Rev., 1999, 79, S23-45. (Pubitemid 29058908)
138. Quinton, P.M.; Bijman, J. Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis. N. Engl. J. Med., 1983, 308, 1185-1189. (Pubitemid 13130837)
139. Hyde, S.C.; Emsley, P.; Hartshorn, M.J.; Mimmack, M.M.; Gileadi, U.; Pearce, S.R.; Gallagher, M.P.; Gill, D.R.; Hubbard, R.E.; Higgins, C.F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature, 1990, 346, 362-365.
140. Welsh, M.J.; Smith, A.E. Molecular Mechanisms of Cftr Chloride Channel Dysfunction in Cystic-Fibrosis. Cell, 1993, 73, 1251-1254. (Pubitemid 23201140)
141. Pedemonte, N.; Diena, T.; Caci, E.; Nieddu, E.; Mazzei, M.; Ravazzolo, R.; Zegarra-Moran, O.; Galietta, L.J. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol. Pharmacol., 2005, 68, 1736-1746. (Pubitemid 41654357)
142. Guengerich, F.P.; Martin, M.V.; Beaune, P.H.; Kremers, P.; Wolff, T.; Waxman, D.J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 1986, 261, 5051-5060. (Pubitemid 17204301)
143. Gonzalez, F.J.; Schmid, B.J.; Umeno, M.; McBride, O.W.; Hardwick, J.P.; Meyer, U.A.; Gelboin, H.V.; Idle, J.R. Human P450PCN1: Sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA, 1988, 7, 79-86. (Pubitemid 18086678)
144. Frizzell, R.A.; Rechkemmer, G.; Shoemaker, R.L. Altered regulation of airway epithelial cell chloride channels in cystic fibrosis. Science, 1986, 233, 558-560. (Pubitemid 16019911)
145. Pedersen, P.S.; Larsen, E.H.; Brandt, N.J. Restitution of Chloride Permeability in Cystic-Fibrosis. Med. Sci. Res.-Biochem., 1987, 15, 151-152.
146. Wang, F.; Zeltwanger, S.; Yang, I.C.H.; Nairn, A.C.; Hwang, T.C. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating-Evidence for two binding-sites with opposite effects. J. Gen. Physiol., 1998, 111, 477-490. (Pubitemid 28136466)
147. Pedemonte, N.; Boido, D.; Moran, O.; Giampieri, M.; Mazzei, M.; Ravazzolo, R.; Galietta, L.J. Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel. Mol. Pharmacol., 2007, 72, 197-207. (Pubitemid 46998539)
148. Cateni, F.; Zacchigna, M.; Pedemonte, N.; Galietta, L.J.; Mazzei, M.T.; Fossa, P.; Giampieri, M.; Mazzei, M. Synthesis of 4-thiophen-2'-yl-1,4- dihydropyridines as potentiators of the CFTR chloride channel. Bioorg. Med. Chem., 2009, 17, 7894-7903.
149. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature, 1997, 389, 816-824. (Pubitemid 27462969)
150. Pan, H.L.; Chen, S.R. Sensing Tissue Ischemia: Another New Function for Capsaicin Receptors? Circulation, 1999, 110, 1826-1831.
151. Hempenstall, K.; Nurmikko, T.J.; Johnson, R.W.; A'Hern, R.P.; Rice, A.S. Analgesic therapy in postherpetic neuralgia: A quantitative systematic review. PLoS Med., 2005, 2, e164.
152. Van der Stelt, M.; Di Marzo, V. Endovanilloids-Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur. J. Biochem., 2004, 271, 1827-1834. (Pubitemid 38657337)
153. Abernethy, D.R.; Schwartz, J.B. Pharmacokinetics of calcium antagonists under development. Clin. Pharmacokinet., 1988, 15, 1-14.
154. Roh, E.J.; Keller, J.M.; Olah, Z.; Iadarola, M.J.; Jacobson, K.A. Structureactivity relationships of 1,4-dihydropyridines that act as enhancers of the vanilloid receptor 1 (TRPV1). Bioorg. Med. Chem., 2008, 16, 9349-9358.
155. Iadarola, M.J.; Max, M.B.; Berman, K.F.; Byas-Smith, M.G.; Coghill, R.C.; Gracely, R.H.; Bennett, G.J. Unilateral decrease in thalamic activity observed with positron emission tomography in patients with chronic neuropathic pain. Pain, 1995, 63, 55-64.
156. Karai, L.; Brown, D.C.; Mannes, A.J.; Connelly, S.T.; Brown, J.; Gandal, M.; Wellisch, O.M.; Neubert, J.K.; Olah, Z.; Iadarola, M.J. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J. Clin. Invest., 2004, 113, 1344-1352. (Pubitemid 39069933)
157. Neubert, J.K.; Karai, L.; Jun, J.H.; Kim, H.S.; Olah, Z.; Iadarola, M.J. Peripherally induced resiniferatoxin analgesia. Pain, 2003, 104, 219-228. (Pubitemid 36835891)
158. Olsen, R.W.; Sieghart, W. GABA A receptors: Subtypes provide diversity of function and pharmacology. Neuropharmacology, 2009, 56, 141-148.
159. Barnard, E.A.; Skolnick, P.; Olsen, R.W.; Mohler, H.; Sieghart, W.; Biggio, G.; Braestrup, C.; Bateson, A.N.; Langer, S.Z. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid A receptors: Classification on the basis of subunit structure and receptor function. Pharmacol. Rev., 1998, 50, 291-313. (Pubitemid 28304030)
160. Moult, P.R. Neuronal glutamate and GABAA receptor function in health and disease. Biochem. Soc. Trans., 2009, 37, 1317-1322.
161. Testa, M.A.; Turner, R.R.; Simonson, D.C.; Krafcik, M.B.; Calvo, C.; Luque-Otero, M.; Grp, N.G.S. Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. J. Hypertens., 1998, 16, 1839-1847. (Pubitemid 28548524)
162. Chesnoy-Marchais, D.; Cathala, L. Modulation of glycine responses by dihydropyridines and verapamil in rat spinal neurons. Eur. J. Neurosci., 2001, 13, 2195-2204. (Pubitemid 32664303)
163. Das, P.; Bell-Horner, C.L.; Huang, R.Q.; Raut, A.; Gonzales, E.B.; Chen, Z.L.; Covey, D.F.; Dillon, G.H. Inhibition of type A GABA receptors by Ltype calcium channel blockers. Neuroscience, 2004, 124, 195-206. (Pubitemid 38186629)
164. Nicoll, R.A.; Malenka, R.C.; Kauer, J.A. Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system. Physiol. Rev., 1990, 70, 513-565. (Pubitemid 20140189)
165. Harayama, N.; Shibuya, I.; Tanaka, K.; Kabashima, N.; Ueta, Y.; Yamashita, H. Inhibition of N-and P/Q-type calcium channels by postsynaptic GABAB receptor activation in rat supraoptic neurones. J. Physiol., 1998, 509, 371-383. (Pubitemid 28286996)
166. Sodickson, D.L.; Bean, B.P. GABAB receptor-activated inwardly rectifying potassium current in dissociated hippocampal CA3 neurons. J. Neurosci., 1996, 16, 6374-6385. (Pubitemid 26337361)
167. Knight, A.R.; Bowery, N.G. The pharmacology of adenylyl cyclase modulation by GABAB receptors in rat brain slices. Neuropharmacology, 1996, 35, 703-712. (Pubitemid 26308547)
168. Fatemi, S.H.; Folsom, T.D.; Reutiman, T.J.; Thuras, P.D. Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum, 2009, 8, 64-69.
169. Ong, J.; Kerr, D.I. Clinical potential of GABA(B) receptor modulators. CNS Drug Rev, 2005, 11, 317-334. (Pubitemid 43100466)
170. Lux-Lantos, V.A.; Bianchi, M.S.; Catalano, P.N.; Libertun, C. GABA(B) receptors in neuroendocrine regulation. Cell. Mol. Neurobiol., 2008, 28, 803-817.
171. Al-Dahan, M.I.; Thalmann, R.H. Effects of dihydropyridine calcium channel ligands on rat brain gamma-aminobutyric acidB receptors. J. Neurochem, 1989, 53, 982-985. (Pubitemid 19207404)
172. Nagarathnam, D.; Wetzel, J.M.; Miao, S.W.; Marzabadi, M.R.; Chiu, G.; Wong, W.C.; Hong, X.; Fang, J.; Forray, C.; Branchek, T.A.; Heydorn, W.E.; Chang, R.S.; Broten, T.; Schorn, T.W.; Gluchowski, C. Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia. J. Med. Chem., 1998, 41, 5320-5333. (Pubitemid 29016323)
173. Marzabadi, M.R.; Hong, X.; Nagarathnam, D.; Miao, S.W.; Chiu, G.; Wong, W.C.; Wetzel, J.M.; Fang, J.; Forray, C.; Chen, T.B.; O'Malley, S.S.; Chang, R.S.; Gluchowski, C. Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg. Med. Chem. Lett., 1999, 9, 2843-2848. (Pubitemid 29481174)
174. Bains, W.; Tacke, R. Silicon chemistry as a novel source of chemical diversity in drug design. Curr. Opin. Drug Discov. Devel., 2003, 6, 526-543. (Pubitemid 36980579)
175. Heinrich, T.; Burschka, C.; Warneck, J.; Tacke, R. Synthesis and pharmacological properties of silicon-containing 1,4-dihydropyridine derivatives: Calcium channel antagonists and alpha 1 adrenoceptor antagonists of the sila-niguldipine type. Organometallics, 2004, 23, 361-366.
176. Fredholm, B.B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 362, 364-374.
177. Marquardt, D.L. Mast cell adenosine receptor characteristics and signaling. Adv. Exp. Med. Biol., 1998, 431, 79-82. (Pubitemid 28236743)
178. Nyce, J.W. Insight into adenosine receptor function using antisense and gene-knockout approaches. Trends Pharmacol. Sci., 1999, 20, 79-83. (Pubitemid 29322315)
179. Tracey, W.R.; Magee, W.; Masamune, H.; Kennedy, S.P.; Knight, D.R.; Buchholz, R.A.; Hill, R.J. Selective adenosine A(3) receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc. Res., 1997, 33, 410-415. (Pubitemid 27075093)
180. Svenningsson, P.; Le Moine, C.; Kull, B.; Sunahara, R.; Bloch, B.; Fredholm, B.B.,Neuroscience. in Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas, United States, 1997; Vol. 80 pp. 1171-1185.
181. Kolachala, V.; Ruble, B.; Vijay-Kumar, M.; Wang, L.; Mwangi, S.; Figler, H.; Figler, R.; Srinivasan, S.; Gewirtz, A.; Linden, J.; Merlin, D.; Sitaraman, S. Blockade of adenosine A2B receptors ameliorates murine colitis. Brit. J. Pharmacol., 2008, 155, 127-137.
182. Hu, P.S.; Lindgren, E.; Jacobson, K.A.; Fredholm, B.B. Interaction of dihydropyridine calcium channel agonists and antagonists with adenosine receptors. Pharmacol. Toxicol., 1987, 61, 121-125. (Pubitemid 17133906)
183. Jiang, J.L.; Van Rhee, A.M.; Melman, N.; Ji, X.D.; Jacobson, K.A. 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A(3) adenosine receptor antagonists. J. Med. Chem., 1996, 39, 4667-4675. (Pubitemid 26382851)
184. Jiang, J.; van Rhee, A.M.; Chang, L.; Patchornik, A.; Ji, X.D.; Evans, P.; Melman, N.; Jacobson, K.A. Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. J. Med. Chem., 1997, 40, 2596-2608. (Pubitemid 27347025)
185. Bauer, R.F.; Collins, P.W.; Jones, P.H. Chapter 19 Agents for the Treatment of Peptic Ulcer Disease. Annu. Rep. Med. Chem., 1987, 22, 191-200.
186. Agrawal, V.K.; Tang, S.B.; Wolowyk, M.W.; Knaus, E.E. Synthesis and activity of pyridine analogues of histamine H2-receptor antagonists. Drug Des. Deliv., 1988, 3, 297-307.
187. Agrawal, V.K.; Tang, S.B.; Wolowyk, M.W.; Knaus, E.E. Synthesis and activity of 1,4-dihydropyridine analogues of histamine H2-receptor antagonists. Drug Des. Deliv., 1990, 6, 101-109. (Pubitemid 20190986)
188. Kalra, S.P.; Kalra, P.S. Is neuropeptide Y a naturally occurring appetite transducer? : Current Opinion in Endocrinology, Diabetes and Obesity. Curr. Opin. Endocrinol. Diabetes Obes., 1996, 3, 157-163.
189. Everitt, B.J.; Hökfelt, T.,The coexistence of neuropeptide Y with other peptides and amines in the central nervous system. in Neuropeptide Y., Ed.: H. T. Füxe K, Lundberg J Raven Press, New York, 1989; Vol. pp. 61-72.
190. Cowley, M.A.; Smart, J.L.; Rubinstein, M.; Cerdan, M.G.; Diano, S.; Horvath, T.L.; Cone, R.D.; Low, M.J. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature, 2001, 411, 480-484. (Pubitemid 32494394)
191. MacNeil, D.J. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr. Top. Med. Chem., 2007, 7, 1721-1733. (Pubitemid 350131009)
192. Inui, A. Neuropeptide Y feeding receptors: Are multiple subtypes involved? Trend. Pharmacol. Sci., 1999, 20, 43-46. (Pubitemid 29322308)
193. Poindexter, G.S.; Bruce, M.A.; LeBoulluec, K.L.; Monkovic, I.; Martin, S.W.; Parker, E.M.; Iben, L.G.; McGovern, R.T.; Ortiz, A.A.; Stanley, J.A.; Mattson, G.K.; Kozlowski, M.; Arcuri, M.; Antal-Zimanyi, I. Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorg. Med. Chem. Lett., 2002, 12, 379-382.
194. Poindexter, G.S.; Bruce, M.A.; Breitenbucher, J.G.; Higgins, M.A.; Sit, S.Y.; Romine, J.L.; Martin, S.W.; Ward, S.A.; McGovern, R.T.; Clarke, W.; Russell, J.; Antal-Zimanyi, I. Dihydropyridine neuropeptide Y Y1 receptor antagonists 2. bioisosteric urea replacements. Bioorg. Med. Chem., 2004, 12, 507-521. (Pubitemid 38064221)
195. Luo, G.; Mattson, G.K.; Bruce, M.A.; Wong, H.; Murphy, B.J.; Longhi, D.; Antal-Zimanyi, I.; Poindexter, G.S. Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14, 5975-5978. (Pubitemid 39531254)
196. Gaggi, R.; Gianni, A.M. Effects of calcium antagonists on biogenic amines in discrete brain areas. Eur. J. Pharmacol., 1990, 181, 187-197. (Pubitemid 20185890)
197. Gaggi, R.; Chirivi, L.; Roncada, P.; Gianni, A.M. Effects of nitrendipine and nisoldipine on biogenic amines in discrete areas of rat brain. Gen. Pharmacol., 1992, 23, 881-888.
198. Gaggi, R.; Gianni, A.M.; Chirivi, L.; Roncada, P. Effects of nimodipine on biogenic amines in discrete brain areas. Pharmacology, 1992, 44, 237-244.
199. Gaggi, R.; Dall'Olio, R.; Roncada, P.; Gianni, A.M. Effects of isradipine and darodipine on serotonergic system of the rat brain. Pharmacol. Biochem. Behav., 1995, 51, 183-187.
200. Gaggi, R.; D'Allolio, R.; Santangelo, M.; Roncada, P. Interactions between darodipine or isradipine and the 5-HT1A receptor agonist 8-OHDPAT in rat brain. Pharmacol. Biochem. Behav., 1997, 58, 299-303. (Pubitemid 27394276)
201. Cortes, R.; Supavilai, P.; Karobath, M.; Palacios, J.M. Calcium antagonist binding sites in the rat brain: Quantitative autoradiographic mapping using the 1,4-dihydropyridines [3H]PN 200-110 and [3H]PY 108-068. J. Neural Transm., 1984, 60, 169-197. (Pubitemid 15177188)
202. Dubovsky, S.L.; Buzan, R.; Thomas, M.; Kassner, C.; Cullum, C.M. Nicardipine improves the antidepressant action of ECT but does not improve cognition. J. ECT, 2001, 17, 3-10. (Pubitemid 32246858)
203. Gaggi, R.; Dall' Olio, R.; Santangelo, M.; Roncada, P. Actions of nimodipine on the serotonergic systems of rat brain. Gen. Pharmacol., 1997, 29, 415-419. (Pubitemid 27412466)
204. Supavilai, P.; Karobath, M. The interaction of [3H]PY 108-068 and of [3H]PN 200-110 with calcium channel binding sites in rat brain. J. Neural Transm., 1984, 60, 149-167. (Pubitemid 15177187)
205. Christiaans, J.A.M.; Timmerman, H. Cardiovascular hybrid drugs: Combination of more the one pharmacological property in one single molecule. Eur. J. Pharm. Sci., 1996, 4, 1-22. (Pubitemid 26016569)
206. Triggle, D.J. Calcium channel antagonists: Clinical uses-past, present and future. Bioch. Pharmacol., 1997, 74, 1-9.